Does PEAOID supplement reduce PMS pain and mood symptoms?

DOCUMENT TYPE: Technical White PaperISSUED BY: Scientific Communications & Regulatory Affairs Division, Aurora Farmabio Pvt. Ltd. ABSTRACT: Premenstrual Syndrome (PMS) presents complex, multi-systemic therapeutic challenges in women's healthcare, driven primarily by late luteal phase progesterone withdrawal and subsequent mast cell hyper-degranulation. This technical white paper characterizes the material properties and multi-channel molecular bioactivity of PEAOID®—a highly purified, unformulated cannabimimetic fatty acid amide active substance (Palmitoylethanolamide). Operating via direct nuclear receptor Peroxisome Proliferator-Activated Receptor-alpha (PPAR-alpha) agonism, the Autacoid Local Inflammation Antagonism (ALIA) cellular mechanism, and indirect endocannabinoid enhancement via competitive Fatty Acid Amide Hydrolase (FAAH) inhibition, PEAOID® effectively stabilizes hyper-responsive tissue structures. KEY CLINICAL TRIAL FINDINGS: • Visceral Analgesia: A daily cyclical dose of 1200 mg of unformulated PEAOID® results in a statistically significant 70.2% reduction in peak pelvic pain indices over a 90-day window (mean VAS scores dropping from 74.2 ± 6.8 mm to 22.4 ± 4.1 mm, p < 0.001). • Somatopsychic Stabilization: Systemic distress metrics (Daily Record of Severity of Problems [DRSP]) tracking irritability and luteal mood shifts decreased by 64.5%. • Biochemical Verification: Fluid biomarker tracking confirmed a 52.1% reduction in local Prostaglandin F2alpha (PGF2alpha) and a 48.6% drop in circulating Tumor Necrosis Factor-alpha (TNF-alpha). • Safety Profile: 0% serious adverse events (SAEs) reported; hepatic and renal metabolic panels remained optimal with a 96.6% treatment compliance rate. FORMULATION & GENOMIC SYNERGY: This dossier details the advanced upstream genomic synergy achieved when pairing the down-stream mast cell stabilization of PEAOID® with the registered plant-derived Cholecalciferol active Vegiferol® to suppress nuclear Cyclooxygenase-2 (COX-2) expression. Manufacturing guidelines for clean-label hard capsules, high-capacity softgels, and bi-layer compressed tablet matrices are included. INTENDED AUDIENCE: This dossier is intended for product managers, procurement teams, formulation scientists, and regulatory affairs executives evaluating premium raw materials for women's health, gynecology, and functional food consumer applications.

Reproduced under CC-BY.